GLP-1R is a well validated target for the treatment of T2DM, with multiple marketed injectable GLP-1 analogues/mimetics that provide glycemic control and weight loss in Type 2 Diabetes patients. Although several of these peptides targeting GLP-1 receptor have reached blockbuster status, their use has been limited by two major factors: 1) route of administration being injections and 2) unfavorable tolerability profile that includes nausea and vomiting.
Recognizing these drawbacks, scientists at
The on-going Phase 2 LOGRA study is assessing the safety and efficacy of TTP273 in Type 2 diabetic subjects on stable doses of metformin. The previous Phase 1b trial of TTP273 showed robust effects on postprandial and fasting glucose. In this study, all doses of TTP273 were well tolerated with no serious adverse events or evidence of significant gastrointestinal side effects. The LOGRA study is expected to read out at the end of this year.
About
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005169/en/
Source:
vTv Therapeutics
Investors
IR@vtvtherapeutics.com
or
Media
Nura
Strong, 336-841-0300 X164
PR@vtvtherapeutics.com